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Abstract
Differentiated carcinoma of the thyroid are one of rare malig-
nancies that is associated with excellent prognosis. Follow-up
with regular thyroglobulin assay and 131I whole-body scan is
capable of detecting residual or recurrent disease with great
sensitivity and specificity. However, there is overwhelming evi-
dence to suggest that this approach is not fail-safe due to in-
creasing reports of false negative and false positive results,
which may result in missed or unwarranted therapy with 131I.
This article will review the current management of differentiated
carcinoma of the thyroid and the possible causes of the repor-
ted inadequacy of thyroglobulin and 131I whole-body scan to
detect residual or recurrent disease, and the increasing role
of alternative imaging, particularly 18F-FDG PET in the manage-
ment of this curable malignancy.
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Introduction
Differentiated carcinoma of the thyroid (DCT) is regarded as
one of the most curable neoplasms. Nevertheless, it has a ten-
dency to develop loco-regional recurrences and distant metastases
in 5–20% and 5–10% respectively, generally in the first years
of follow-up, but sometimes after many years. The American 10-year
survival rates of a large cohort of patients with papillary and follic-
ular carcinoma have recently been shown by Schlumberger et al
to be 93% and 85% respectively [1].
The European 5-year survival rates for DCT are somewhat lower
at 72% for men and 80% for women [2] with even lower figures for
the UK (64% for men and 75% for women). Concerns have been
raised that DCT is not well managed in Britain and Europe and
that efforts should be made to improve adequacy of initial treat-
ment (surgery and radioiodine therapy) and follow-up procedures
[3]. The provision of agreed protocols and centralisation of exper-
tise is strongly emphasised.
The post surgical management of DCT is well established and
consists of:
— total or near-total thyroidectomy;
— ablation of remnant thyroid tissue with iodine-131 (131I);
— suppression of endogenous TSH with life-long thyroxine
replacement;
— regular thyroglobulin (Tg) assays;
— periodic 131I whole-body scan (131I WBS) to detect possible
recurrence or metastasis.
The value of the first three elements of this strategy is undis-
puted. Total thyroidectomy followed by remnant ablation are known
to minimise recurrence rate and improve survival and effective-
ness of Tg assay by eliminating normal Tg production. In addi-
tion, they will enhance the sensitivity of 131I WBS by keeping com-
petitive uptake of residual thyroid tissue to the minimum.
However, there is increasing evidence to suggest that reliance
on the last two elements of this strategy (periodic Tg assays and
131I WBS) does not bestow full confidence in ruling out recurrent or
metastatic disease. False positive and false negative Tg results
[4–7] and 131I WBS [5, 8] are well documented with the potential
of missed or needless 131I therapy.
Imaging with 131I
131I WBS remains by far the most cost-effective and widely used
imaging method for follow-up of patients with DCT. It has favour-
able features that include low cost and availability, physiological
uptake by thyroid and differentiated tumour cells and a gamma
emission that is far from ideal but adequate for imaging. Its dis-
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advantages include relatively low specificity and sensitivity, its ten-
dency to induce stunning and the need for intensive patient prepa-
ration including withdrawal of thyroxine for 4–6 weeks and adop-
ting a strict iodine-free diet that may not appeal to all patients.
Limitations of 131I WBS
Low sensitivity
Comparative studies have shown higher sensitivity of Tg mea-
surements over 131I WBS in DCT. In a study by Ronga et al [9]
the sensitivity of 131I WBS was 48% compared to 96% for Tg. Others
have shown variable sensitivities but not exceeding 70–80%.
The low sensitivity of 131I WBS can result from one or more
of the followings:
— saturation of sodium-iodide symporters (NIS) by iodine rich
diet, medications or use of contrast media;
— inadequate TSH elevation mostly due to non-compliance;
— metastases too small to be detected by camera resolution;
— loss of ability to take up 131I due to de-differentiation of tumour
cells as a result of an acquired mutation of NIS. Immunohis-
tochemical staining of malignant thyroid cells has shown
a reduction in Na/I symporters in primary DTC and lymph node
metastasis that did not accumulate 131I [10].
Measures to overcome these difficulties include strict patient
preparation and the use of recombinant human TSH (rhTSH) to
establish a satisfactory TSH levels, improving image quality and
resolution by administering higher 131I doses [11] and the use
of retinoic acid in unresponsive tumours. However, in clinical prac-
tice, an alternative imaging is usually employed.
Low specificity
Acquisition errors, artefacts, physiologic distribution and non-thy-
roidal pathologic uptake of 131I constitute the majority of false positive
results. A list of possible causes of a false positive scan is shown in
Table 1. It is prudent to keep a comprehensive and updated list of
these conditions to aid in the interpretation of scans [12]. Correla-
tion with ultrasound, computed tomography and other imaging
modalities can be helpful (Fig. 1).
De-differentiation of DCT
Throughout the long-term survival of patients with DCT, loss
of differentiation is noted in one third of patients resulting in loss
of thyroid specific function and increased tumour grading and
severity. As a consequence of that, lesser Tg production and higher
rate of false negative 131I WBS will be noted.
The use of retinoic acids can reverse de-differentiation of DCT
and improve diagnostic and therapeutic potential of 131I. Simon et al [13]
used 13-cis-retinoic acid in 50 patients with DCT and noted an in-
crease in 131I uptake in 21 patients with an overall response (changes
in Tg production, 131I uptake and tumour regression) in 38%.
Limitations of Tg measurements
Since the introduction of Tg assay as a tumour marker for
DCT in the early 80s, comparative studies have shown its sensi-
tivity in detecting residual or recurrent disease [9]. While it is still
regarded as the gold standard against which other investiga-
tions, specially imaging, are compared, careful interpretation of
results must be undertaken in the presence of thyroglobulin an-
tibodies (TgAbs) that may invalidate them and contribute to false
negative values. Another source of false negative Tg value is
measurement under thyroxine suppressive effect, and it is strong-
ly recommended that Tg measurement be done under TSH stim-
ulation that is similarly achieved by withdrawal of thyroxine
or administration of recombinant human TSH (rhTSH) [14]. Diffe-
rent assay methods can produce different values and establishing
a normal reference value for each laboratory is essential [15]. De-
-differentiation is another major factor in producing false nega-
tive results, and Tg assay has been shown to have a reduced
sensitivity of 55% in patients with negative 131I WBS who had
proven metastasis [5].
The above discussion raises a critical question: How confident
are we in ruling out disease when both 131I and Tg are negative?
Alternative imaging to 131I
Despite loss of differentiation, tumour cells may continue to
show elevated Tg as selective destruction of iodine-avid cells fo-
llowing therapy may leave behind clones that show no 131I uptake
while retaining their ability to produce Tg [16, 17]. Thus, the entity
of ‘Tg positive-131I WBS negative’ recurrence or metastasis has
emerged. There are clear indications that these lesions are asso-
ciated with worse prognosis and shortened survival compared to
lesions that show avidity to 131I [10, 18, 19] due to higher de-differ-
entiation and growth rate. Some authors have suggested blind
131I therapy in all such cases and express doubt on the value
of non-iodine imaging [20–22]. However, pre-treatment imaging
remains valuable to assist in the choice of therapeutic approach
and post-therapy follow-up. This is done using one or more alter-
native radiopharmaceuticals supplemented with cross sectional im-
aging (CT, MRI, high resolution US) if and when necessary (Fig. 2).
Contrast CT is to be avoided if a therapy dose is planned.
Various reports described the use of 201Tl, 99mTc-MIBI, 99mTc-
-tetrofosmin 99mTc-MDP 111I-octreotid and positron emission tomog-
raphy with 18F-fluorodeoxyglucose (18F-FDG-PET) for the detec-
tion of Tg positive-131I negative DCT. There is a wealth of literature,
spanning the last 2 decades, that examines the individual roles
of these radiopharmaceuticals and compares each against one
or more of the others. For practical purposes, they can be re-
viewed as two separate groups.
Table 1. Some causes of false positive 131I WBS
Head and neck
Thymus, dacryocystitis, chronic sinusitis, artificial eye, wig
Pulmonary
Tracheostomy, inflammatory disease, carcinoma
GIT
Meckel’s, gastric adenocarcinoma, constipation
GUT
Poor renal function, cysts, ectopic kidney, cystadenoma, hydrocele
CVS
Pectus excavatum
CNS
Meningioma
Miscellaneous
Body secretion, skin burns, psoriasis, lactating breast
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Gamma camera imaging
A great proportion of studies relates to 99mTc-MIBI. Almeida-
-Filho et al [24] evaluated 99 patients with DCT, while on suppres-
sive thyroxine treatment, with whole-body 99mTc-MIBI and com-
pared the results with 131I, using Tg as a gold standard. They found
whole-body 99mTc-MIBI to be concordant with Tg in 96% and dis-
cordant in 4% of cases. Such high sensitivity has not been shown
by other studies, and some authors recommend combination with
US [25] for better yield. Some have highlighted better sensitivity
for metastatic disease but lower sensitivity in detecting remnant
thyroid tissue and lung metastases [26, 27].
In general, 99mTc labelled radiopharmaceuticals have better
resolution than 201Tl but head to head comparison between
99mTc-MIBI and 201Tl showed very similar results with sensitivity
of 53%, high specificity of 100% and an overall accuracy of 69%
for both [28]. This comparative study employed planar images that
missed residual cancer in high cervical lymph nodes adjacent to
salivary gland activity, in small nodes of < 1 cm deep in the neck or
chest, and diffuse pulmonary micro metastases. A similar com-
parative study between 201Tl and 99mTc-tetrofosmin [29] revealed
identical sensitivity of 79.4% in detecting metastatic lesions com-
pared to 67.6% for 131I. However, sensitivity for detecting lung me-
tastases was equally lower at 68.8%.
Imaging with 201Tl and 99mTc-tetrofosmin was similar to that
with 99mTc-MIBI in showing reduced sensitivity for detecting thy-
roid remnants but higher sensitivity in metastatic disease. However,
some studies have shown good results with 201Tl in the pre-abla-
tive states. Carril et al [30] found at least one lesion that was 131I
negative but 201Tl positive in 31 patients (15 pre-ablative and
16 post-ablative) out of a cohort of 116 patients with DCT. When
discordant results were analysed, 201Tl positive-131I negative lesions
were more likely to be associated with high Tg levels, while 131I posi-
tive-201Tl negative lesions were associated with normal Tg levels.
As is the case with 99mTc-MIBI, imaging with 201Tl and 99mTc-
-tetrofosmin showed no difference in sensitivity when patients were
on or off thyroxine replacement therapy [31].
There is limited experience with 111I-octreotide [32] and 99mTc-
-MDP [33], but the available data suggests lower specificity and
confirms their role in complementing rather than replacing 131I WBS.
18F-FDG-PET imaging in DTC
Metabolic imaging was based on early observation by War-
burg that tumours utilise more glucose than normal cells [34] and
was made possible by using positron emitters that match the in-
ternal biological milieu. Experience with 18F-FDG-PET, with its
superior resolution and sensitivity, has shown it to be an effective
modality in the management of patients with a wide variety of can-
cers [35]. Most importantly, it is a good marker of proliferative
potential and aggressiveness in lung cancer, lymphoma, brain
and soft tissue tumours [36–39].
Early observation in DTC showed that metastases could
accumulate only 18F-FDG, only 131I, or both with higher 18F-FDG in
progressive metastases [40]. Feine et al [41] confirmed this ”flip
flop” phenomenon in a series of 41 patients and described alter-
nating behaviour in metastases (those trapping 131I showing no
18F-FDG uptake and vice versa) in 30 patients. They found that
metastases with positive 131I and negative 18F-FDG uptake repre-
sent better differentiation and tumour grade, while those with neg-
Figure 1. False positive 131I WBS. A. 131I WBS showing uptake in a bowel
loop simulating uptake in right lobe of the liver. The loop was displaced
due to previous right liver lobectomy; B. CT showing upward displace-
ment of bowel.
A
B
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Sites of metastasis that demonstrate better 18F-FDG uptake
are cervical and mediastinal lymph nodes whereas lung and
bone lesions showed less uptake compared to 131I WBS and
99mTc-MIBI [5, 42, 44, 52]. Figures 3 and 4 are examples of flip-
flop phenomenon with discordant uptake of 18F-FDG and 131I.
The issue of performing 18F-FDG PET scanning under TSH stimu-
lation is controversial though Moog et al [53] have shown a con-
vincing improvement in 18F-FDG uptake under TSH stimulation.
Summary
The current strategy of reliance on Tg assay and 131I WBS in
the follow-up in DTC is inadequate due to reduced sensitivity and
specificity particularly when tumours undergo de-differentiation.
In these situations, the tumours become aggressive with higher
grade and reduced survival. The difficulty in detecting such recur-
rences or metastases may result in inappropriate management.
The use of 99mTc-MIBI or 201Tl, supplemented with CT and US
can be helpful in a proportion of cases. However, the detection of
de-differentiation requires an improved sensitivity and specificity
through the use of a radiopharmaceutical with uptake that corre-
lates well with aggressive and high-grade tumours, and an imag-
ing techniques that provides tomography with higher resolution.
Both criteria are met by employing 18F-FDG-PET. It has
a mechanism of uptake that correlates well with higher aggres-
siveness and grading of tumours and has been shown to detect
lesions that are not visible on 131I WBS with excellent specificity.
The superb resolution of PET and the facility of whole-body imag-
ing give this technique the edge over cross sectional imaging when
provisional localisation of recurrence is not available. The demon-
Figure 2. Alternative imaging in DCT. A. Chest X ray of a 52-year-old male with follicular carcinoma of the thyroid presented with rising Tg and RUL shadow
(arrow); B. CT scan confirmed presence of a well--defined rounded mass in the same area thought to be a benign hamartoma; C. Whole-body 131I scan was
negative as was 201Th scan D; E. Posterior chest 99mTc--MIBI scan demonstrated uptake in the lesion that was shown on biopsy to be metastatic disease.
ative 131I and positive 18F-FDG uptake were regarded of higher
malignancy, a view shared with others [18, 40, 42, 43]. The results
of a multicentre study in 222 patients with DTC showed a sensitiv-
ity of 85% and specificity of 90% for patients with negative 131I
WBS [42]. When the results of 18F-FDG PET and 131I WBS were
considered in combination, tumour tissue was missed in only 7%
of lesions.
There is general agreement that 18F-FDG-PET offers increased
detection and provides information as far as differentiation and
grading is concerned [5, 18, 40–50]. Changes in management
and prognosis are greatly aided by imaging with 18F-FDG PET.
Two recent studies have shown a change of management of 56%
and 78% of true positive 18F-FDG PET cases [43, 49]. The prog-
nostic value of 18F-FDG PET is demonstrated in the linear relation-
ship with Tg and higher-grade tumours [40–44, 49, 50] and discor-
dance with 131I WBS [5, 18, 41, 42, 44, 49, 50]. Boerner et al [51]
showed that 18F-FDG standard uptake value (SUV) decreased sig-
nificantly during isotretinoin therapy in association with increased
131I uptake (as a marker of differentiation), but subsequently in-
creased after withdrawal suggesting a tendency towards lower
18F-FDG uptake in tumours with a better outcome.
In addition to its prognostic value, 18F-FDG-PET can be cost effec-
tive in limiting unnecessary therapy, as high dose 131I therapy have little
or no effect on the viability of 18F-FDG-avid metastatic lesions [18].
18F-FDG-PET can be helpful when Tg is suspected to be false
negative. An interesting study by Chung et al [5] on 54 patients
with papillary carcinoma and negative 131I WBS showed abnormal
18F-FDG uptake in 31 patients with 94% sensitivity and 95% speci-
ficity whereas Tg was elevated in 18 patients with 55% sensitivity
and 76% specificity.
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Figure 3. Flip-flop phenomenon — a 38-year-old female with DCT and rising Tg. A. Diagnostic 131I WBS appears normal; B. Coronal section from an
18FDG-PET showing uptake in thyroid bed, prompting a therapy dose with 131I; C. 131I post therapy scan showing similar uptake in thyroid bed but in addi-
tion showing diffuse and global uptake in both lungs.
An important aspect of 18F-FDG PET imaging, compared to
other non-iodine imaging, is its ability to provide prognostic infor-
mation that has helped to change the management of patients
with DTC in a large proportion of true positive cases. Likewise,
it can help detect tumour foci when Tg is normal due to loss
of production caused by de-differentiation.
Unfortunately, there is a worldwide deficiency in the provision
of PET scanners and cyclotrons extending to some developed
countries such as the UK.  Until this is reversed, the management
of DTC will continue to depend on the combination of Tg assay
and 131I WBS. However, the increasing awareness of dedifferenti-
ation requires vigilance and frequent supplementation with
99mTc-MIBI, 201Tl and morphological imaging.
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